Dr. Matthew Scheideman has developed expertise in various aspects of drug research and development from a decade of experience as a medicinal chemist in both the biotech and pharmaceutical industries. He strives to apply this firsthand experience by helping clients build and maintain robust patent portfolios in a number of therapeutic and technology areas. Matt’s practice includes drafting complex patent applications, prosecuting multi-jurisdictional patent applications, and assisting with freedom-to-operate, invalidity and patentability opinions.
Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street.
